Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accounts Payables: 2020-2025

Historic Accounts Payables for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $3.4 million.

  • Janux Therapeutics' Accounts Payables rose 37.90% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 37.90%. This contributed to the annual value of $4.0 million for FY2024, which is 66.09% up from last year.
  • Per Janux Therapeutics' latest filing, its Accounts Payables stood at $3.4 million for Q3 2025, which was down 2.36% from $3.5 million recorded in Q2 2025.
  • Janux Therapeutics' Accounts Payables' 5-year high stood at $4.0 million during Q4 2024, with a 5-year trough of $354,000 in Q2 2021.
  • Moreover, its 3-year median value for Accounts Payables was $2.4 million (2023), whereas its average is $2.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 747.46% in 2022, then slumped by 36.33% in 2023.
  • Over the past 5 years, Janux Therapeutics' Accounts Payables (Quarterly) stood at $2.5 million in 2021, then dropped by 12.16% to $2.2 million in 2022, then grew by 12.27% to $2.4 million in 2023, then surged by 66.09% to $4.0 million in 2024, then skyrocketed by 37.90% to $3.4 million in 2025.
  • Its Accounts Payables was $3.4 million in Q3 2025, compared to $3.5 million in Q2 2025 and $2.4 million in Q1 2025.